Drug Trial Radar · NCT03172208
Caplacizumab Single and Multiple Dose Study in Healthy Japanese and White Subjects.
Last checked: Nov 20, 2026Latest source record: Nov 14, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
60
Actual
Start
Jun 5, 2017
Primary completion
Oct 19, 2017
Study completion Oct 19, 2017
Sponsor
- Lead sponsor
- Ablynx, a Sanofi companyIndustry
- Sponsor type
- Industry
- First posted
- Jun 1, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Primary objective: To assess the safety and tolerability of single ascending intravenous (i.v.) doses, a single subcutaneous (s.c.) dose of caplacizumab (Part I), and multiple s.c. doses of caplacizumab (Part II) in Japanese subjects. Secondary objectives: * To compare the pharmacokinetic (PK) and pharmacodynamic (PD) profiles (total vWF:Ag concentration levels \[vWF:Ag\], coagulation factor VIII \[FVIII:C\], and ristocetin cofactor activity \[RICO\]) after single i.v. or s.c. administration of caplacizumab in Japanese and White subjects. * To evaluate the immunogenicity of caplacizumab (anti-drug antibodies \[ADA\]) in Japanese subjects.
Conditions
- Healthy Volunteers
Interventions
Caplacizumab Dose 1 iv (single-dose)Biological
Single intravenous (iv) administration of Caplacizumab Dose 1
Caplacizumab Dose 2 iv (single-dose)Biological
Single intravenous (iv) administration of Caplacizumab Dose 2
Caplacizumab Dose 2 sc (single-dose)Biological
Single subcutaneous (sc) administration of Caplacizumab Dose 2
Caplacizumab Dose 2 sc (multiple-dose)Biological
Once daily subcutaneous (sc) administration of Caplacizumab Dose 2 during 7 consecutive days
Placebo iv (single-dose)Other
Single intravenous (iv) administration of Placebo
Placebo sc (single-dose)Other
Single subcutaneous (sc) administration of Placebo
Placebo sc (multiple-dose)Other
Once daily subcutaneous (sc) administration of Placebo during 7 consecutive days
Primary outcomes
What the sponsor says the trial is designed to measure.
- The number of treatment-emergent adverse events (Safety and Tolerability)Time frame: From signing of informed consent form until Day 28 (single-dose part) or Day 34 (multiple dose part)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Investigator Site
Glendale, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.